[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342592-105":59,"doc-detail-342592-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","signaling-lymphocytic-activation-molecule-family-receptors-as-potential-immune-therapeutic-targets-in-solid-tumors","Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors","","Cancer immunotherapy has reshaped solid-tumor care yet benefits only a subset of patients, owing to complex tumor microenvironment (TME)–driven resistance. Signaling lymphocytic activation molecule family (SLAMF) receptors are widely studied for their influence on immune contexture, with nine mainly immune-cell–expressed receptors also found on cancer cells. This review summarizes SLAMF receptor expression in solid tumors and tumor-infiltrating immune cells, links receptor patterns to patient outcomes, and evaluates SLAMF-targeted strategies to improve therapeutic efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/signaling-lymphocytic-activation-molecule-family-receptors-as-potential-immune-therapeutic-targets-in-solid-tumors/342592/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/signaling-lymphocytic-activation-molecule-family-receptors-as-potential-immune-therapeutic-targets-in-solid-tumors/342592.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does immunotherapy work for only some patients with solid tumors?","Question",{"text":112,"@type":113},"Responses are limited by tumor microenvironment factors that promote resistance. These include inadequate infiltration of cytotoxic lymphocytes and immunosuppressive TME populations that inhibit anti-cancer immunity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are SLAMF receptors and where are they expressed?",{"text":117,"@type":113},"SLAMF receptors are cell-surface glycoproteins in the immunoglobulin superfamily involved in immune functions. They consist of nine mainly immune-cell–expressed receptors, but they can also be detected in cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the potential therapeutic value of targeting SLAMF receptors?",{"text":121,"@type":113},"The review discusses therapeutic strategies aimed at SLAMF receptors to improve solid-tumor outcomes. By influencing the tumor immune microenvironment, SLAMF-targeted approaches may enhance anti-cancer immunity and clinical benefit.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342592,1790156033,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","TYPE Review  \nPUBLISHED 27 February 2024  \nDOI 10.3389/fimmu.2024.1297473  \nOPEN ACCESS  \nEDITED BY  \nXuanbin Wang,  \nHubei University of Medicine, China  \nREVIEWED BY  \nGuillaume Darrasse-Jeze, Universite´ de Paris, France  \nPooya Farhangnia,  \nIran University of Medical Sciences, Iran Ali-Akbar Delbandi,  \nIran University of Medical Sciences, Iran  \n*CORRESPONDENCE  \nE. Gulsen Gunes  \n [eggunes@coh.org](eggunes@coh.org)  \n†These authors have contributed equally to this work  \nRECEIVED 20 September 2023  \nACCEPTED 05 February 2024  \nPUBLISHED 27 February 2024  \nCITATION  \nGunes M, Rosen ST, Shachar I and Gunes EG (2024) Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors. Front. Immunol. 15:1297473 .  \ndoi: 10.3389/fimmu.2024.1297473  \nCOPYRIGHT  \n© 2024 Gunes, Rosen, Shachar and Gunes.  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nSignaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors  \nMetin Gunes 1†, Steven T. Rosen 1,2, Idit Shachar 3 and E. Gulsen Gunes 1,2,4*†  \n1 Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Los Angeles, CA, United States, 2Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Los Angeles, CA, United States, 3 Department of System Immunology, Weizmann Institute of Science, Rehovot, Israel, 4Toni Stephenson Lymphoma Center, City of Hope, Los Angeles, CA, United States  \nRecently, cancer immunotherapy has revolutionized cancer treatment. Various forms of immunotherapy have a manageable safety proﬁle and result in prolongation of overall survival in patients with solid tumors, but only in a proportion of patients. Various factors in the tumor microenvironment play critical roles and may be responsible for this lack of therapeutic response. Signaling lymphocytic activation molecule family (SLAMF) members are increasingly being studied as factors impacting the tumor immune microenvironment. SLAMF members consist of nine receptors mainly expressed in immune cells. However, SLAMF receptors have also been detected in cancer cells, and they may be involved in a spectrum of anti-tumor immune responses. Here, we review the current knowledge of the expression of SLAMF receptors in solid tumors and tumor-inﬁltrating immune cells and their association with patient outcomes. Furthermore, we discuss the therapeutic potential of targeting SLAMF receptors to improve outcomes of cancer therapy in solid tumors. We believe the research on SLAMF receptor-targeted strategies may enhance anti-cancer immunity in patients with solid tumors and improve clinical outcomes.  \nKEYWORDS  \nsignaling lymphocytic activation molecule family, SLAMF, cancer immunology, immunotherapy, solid tumors, tumor microenvironment  \n1 Introduction  \nCancer immunotherapy has revolutionized cancer treatment in the past decade, becoming the fourth pillar of treatment next to surgery, chemotherapy, and radiotherapy. Blocking immune checkpoints with monoclonal antibodies has improved outcomes in solid tumor patients (1) . Furthermore, cellular therapies, particularly chimeric  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nantigen receptor (CAR)-T cell therapy, have shown high effectiveness for various cancers (2) . However, many patients with solid tumors do not beneﬁt from these strategies. This has warranted research into resistance mechanisms and other treatment options. Some factors in the tumor microenvironment (TME) of solid tu","cbCaisXWQTdqircu","https://ap.wps.com/l/cbCaisXWQTdqircu","pdf",974065,11,"English","# Introduction\n# SLAMF receptors","[{\"question\":\"Why does immunotherapy work for only some patients with solid tumors?\",\"answer\":\"Responses are limited by tumor microenvironment factors that promote resistance. These include inadequate infiltration of cytotoxic lymphocytes and immunosuppressive TME populations that inhibit anti-cancer immunity.\"},{\"question\":\"What are SLAMF receptors and where are they expressed?\",\"answer\":\"SLAMF receptors are cell-surface glycoproteins in the immunoglobulin superfamily involved in immune functions. They consist of nine mainly immune-cell–expressed receptors, but they can also be detected in cancer cells.\"},{\"question\":\"What is the potential therapeutic value of targeting SLAMF receptors?\",\"answer\":\"The review discusses therapeutic strategies aimed at SLAMF receptors to improve solid-tumor outcomes. By influencing the tumor immune microenvironment, SLAMF-targeted approaches may enhance anti-cancer immunity and clinical benefit.\"}]","Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors | PDF",1790047290,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd4d6acf7107e186684cd9fb9a30cd51.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc2d1da6da6f74b7c81658c5fa97ca1d.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/468b447ca3410c64fbd7b9d2cf5db82c.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/034a5f4da13f950596b1f389fdd64f8f.webp",980,1385]